HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
September 07 2022 - 7:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapies based on its proprietary arenavirus
platform
, today announced that HOOKIPA’s
management team will participate in the following upcoming investor
conferences:
- Morgan Stanley Global Healthcare Conference, September
12-14, New YorkFireside Chat: September 13, 12:55pm
ET
- H.C. Wainwright Global Investment Conference, September
12-14, New York
The Morgan Stanley Fireside Chat webcast will be
available within the Investors & Media section of HOOKIPA’s
website at https://ir.hookipapharma.com/events. Archived replays
will be accessible for 30 days following each event.
About HOOKIPAHOOKIPA Pharma
Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company
focused on developing novel immunotherapies, based on its
proprietary arenavirus platform, which are designed to mobilize and
amplify targeted T cells and thereby fight or prevent serious
disease. HOOKIPA’s replicating and non-replicating technologies are
engineered to induce robust and durable antigen-specific CD8+ cell
responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline
includes its wholly owned investigational arenaviral
immunotherapies targeting HPV16+ cancers, prostate cancer,
KRAS-mutated cancers (including colorectal, pancreatic and lung),
and other undisclosed programs. In addition, HOOKIPA aims to
develop functional cures for HBV and HIV in collaboration with
Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
Media |
Investors |
Michael Szumera |
Matt Beck |
Executive Director - Communications |
Executive Director – Investor Relations |
michael.szumera@hookipapharma.com |
matthew.beck@hookipapharma.com |
+1 917 561 8905 |
+1 917 209 6886 |
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024